[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Invests US$195 Million To Expand U.S. Pharmaceutical Production",
    "summary": "AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API production, reflecting its long-term commitment to U.S. manufacturing. Over the last quarter, AbbVie shares rose 12%, a movement that aligns with broader market gains, including new highs for the S&P 500 and Nasdaq. While the company's lackluster earnings report dampened enthusiasm, its raised earnings guidance and FDA-approved label expansions supported investor confidence. The...",
    "url": "https://finnhub.io/api/news?id=d87b226fb45bf14efd231cd14f7817845024b0178d23abc902e2582444cce869",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755105882,
      "headline": "AbbVie (ABBV) Invests US$195 Million To Expand U.S. Pharmaceutical Production",
      "id": 136339488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API production, reflecting its long-term commitment to U.S. manufacturing. Over the last quarter, AbbVie shares rose 12%, a movement that aligns with broader market gains, including new highs for the S&P 500 and Nasdaq. While the company's lackluster earnings report dampened enthusiasm, its raised earnings guidance and FDA-approved label expansions supported investor confidence. The...",
      "url": "https://finnhub.io/api/news?id=d87b226fb45bf14efd231cd14f7817845024b0178d23abc902e2582444cce869"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d381cefc19f33394d94482eeaf357da9253fc5e87746f6d89cab6428a5f08439",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755102660,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 136385167,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d381cefc19f33394d94482eeaf357da9253fc5e87746f6d89cab6428a5f08439"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to build API plant in Illinois as it steps up US production",
    "summary": "The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.",
    "url": "https://finnhub.io/api/news?id=fcaeee92f0c5dce1d8ec8a42b49ff5fa00c64911d8850df63d35892f55c5d6ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755082800,
      "headline": "AbbVie to build API plant in Illinois as it steps up US production",
      "id": 136339489,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.",
      "url": "https://finnhub.io/api/news?id=fcaeee92f0c5dce1d8ec8a42b49ff5fa00c64911d8850df63d35892f55c5d6ec"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie expands North Chicago API production with $195m investment",
    "summary": "Construction of the new API facility will commence in autumn 2025.",
    "url": "https://finnhub.io/api/news?id=3fd52d5c3216ebebd45f9210fe0e49f473e5010b8c5b73113f8538f0439b2558",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755077465,
      "headline": "AbbVie expands North Chicago API production with $195m investment",
      "id": 136328252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Construction of the new API facility will commence in autumn 2025.",
      "url": "https://finnhub.io/api/news?id=3fd52d5c3216ebebd45f9210fe0e49f473e5010b8c5b73113f8538f0439b2558"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys",
    "summary": "See here for more on July's investment insights: record-breaking dividends, high-yield BDCs, and strategies for steady income growth.",
    "url": "https://finnhub.io/api/news?id=642c79a5d7ace207c9d722f9b6e969419b05a47cf1edf5c3505e32f7b283a55b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755072900,
      "headline": "My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys",
      "id": 136327951,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "See here for more on July's investment insights: record-breaking dividends, high-yield BDCs, and strategies for steady income growth.",
      "url": "https://finnhub.io/api/news?id=642c79a5d7ace207c9d722f9b6e969419b05a47cf1edf5c3505e32f7b283a55b"
    }
  },
  {
    "ts": null,
    "headline": "ABBV Q2 Deep Dive: Immunology and Neuroscience Growth Outpace Aesthetics, Guidance Trimmed",
    "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=4659e4eda3ed7e538e13a01a0ac86f358d5c113841c00a21fe3429945578b8df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057820,
      "headline": "ABBV Q2 Deep Dive: Immunology and Neuroscience Growth Outpace Aesthetics, Guidance Trimmed",
      "id": 136328253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=4659e4eda3ed7e538e13a01a0ac86f358d5c113841c00a21fe3429945578b8df"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From AbbVie’s Q2 Earnings Call",
    "summary": "AbbVie’s second quarter saw a significant positive market response, driven by robust sales from its immunology and neuroscience portfolios. Management emphasized that continued uptake in Skyrizi and Rinvoq, along with strength in the neuroscience franchise (particularly Vraylar, Vyalev, and migraine therapies), fueled the quarter’s revenue and margin expansion. CEO Robert Michael cited “continued robust performance from Skyrizi and Rinvoq” and called out “strong double-digit growth from neurosci",
    "url": "https://finnhub.io/api/news?id=36517b07aed3b518936d5e74551ec831da83dc745420a3b8b037c1db3fecac6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057013,
      "headline": "5 Insightful Analyst Questions From AbbVie’s Q2 Earnings Call",
      "id": 136328254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s second quarter saw a significant positive market response, driven by robust sales from its immunology and neuroscience portfolios. Management emphasized that continued uptake in Skyrizi and Rinvoq, along with strength in the neuroscience franchise (particularly Vraylar, Vyalev, and migraine therapies), fueled the quarter’s revenue and margin expansion. CEO Robert Michael cited “continued robust performance from Skyrizi and Rinvoq” and called out “strong double-digit growth from neurosci",
      "url": "https://finnhub.io/api/news?id=36517b07aed3b518936d5e74551ec831da83dc745420a3b8b037c1db3fecac6a"
    }
  }
]